Skip to content

Human Rabies Immunoglobulin (HRIG)- Dosage Determination and Interference With the Active Immune Response

Human Rabies Immunoglobulin (HRIG)- Dosage Determination and Interference With the Active Immune Response

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01610362
Enrollment
50
Registered
2012-06-04
Start date
2012-06-30
Completion date
2018-04-30
Last updated
2018-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rabies

Keywords

rabies, immunoglobulin, dosage

Brief summary

Dosage of rabies immune globulin was calculated from the victim's body weight, then the amount of rabies immune globulin would be injected as much as possible to all of the wounds. Increase dosage of rabies immune globulin was needed in situation of multiple severe bite-wounds especially among children whose had lower body weight than adults. Our study would be conducted in order to determine whether the increase dosage of rabies immune globulin would interfere with the protective antibody levels against rabies.

Detailed description

* Controlled trial study. * All 50 volunteers who had never had rabies immunization would be enrolled and designated into 2 groups. group 1 : 15 Healthy volunteers age 18 - 60 yr who were attacked by mammals, possible exposed to rabies and had WHO category III exposure, all receive standard post - exposure rabies treatment with 5-dose intramuscular rabies vaccine on day 0,3,7,14,28 and 20 IU/kg of human rabies immune globulin (HRIG). group 2 : 35 Healthy volunteers age 18 - 60 yr receive 5-dose intramuscular rabies vaccine on day 0,3,7,14,28 and 40 IU/kg of human rabies immune globulin (HRIG). 5 cc - Blood would be drawn from all volunteers before vaccination and on day 14, 28 and 90 for rabies neutralizing antibody titers (RNab). The GMTs of RNab among both groups would be analyzed and compared.

Interventions

BIOLOGICALHuman Rabies Immune Globulin

HRIG 20 IU/kg and 40 IU/kg would be given once to the volunteers on day 0

Sponsors

Queen Saovabha Memorial Institute
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* healthy volunteers age 18-60 years.

Exclusion criteria

* received prior rabies immunization * pregnancy * immunocompromised conditions

Design outcomes

Primary

MeasureTime frameDescription
Rabies Neutralizing antibody titers in volunteers who receive HRIG 40 IU/kgChange from baseline of Rabies Neutralizing Antibody Titers at 3 - month periodRabies Neutralizing antibody titers in volunteers who receive HRIG 40 IU/kg would be determined on day 0,14, 28 and 90. Rnab titers above 0.5 IU/ml would be considered as protective levels as WHO recommendation.

Secondary

MeasureTime frameDescription
Number of participants who have Rabies Neutralizing antibody titers above protective levels.Number of participants who have Rabies Neutralizing antibody titers above protective levels at 3-month period..Number of participants who have Rabies Neutralizing antibody titers above protective levels (\> 0.5 IU/mL as recommended by WHO)at 3-month period.

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026